NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category (Descending) | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
42737-0104-05 | 42737-0104 | temozolomide | TEMOZOLOMIDE | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec. 31, 2018 | Jan. 24, 2019 | In Use |
42737-0104-14 | 42737-0104 | temozolomide | TEMOZOLOMIDE | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec. 31, 2018 | Jan. 24, 2019 | In Use |
42737-0105-05 | 42737-0105 | temozolomide | TEMOZOLOMIDE | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec. 31, 2018 | Jan. 24, 2019 | In Use |
42737-0105-14 | 42737-0105 | temozolomide | TEMOZOLOMIDE | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec. 31, 2018 | Jan. 24, 2019 | In Use |
42737-0106-05 | 42737-0106 | temozolomide | TEMOZOLOMIDE | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec. 31, 2018 | Jan. 24, 2019 | In Use |
43063-0439-30 | 43063-0439 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Aug. 22, 2012 | April 6, 2021 | In Use |
79802-0200-30 | 79802-0200 | belumosudil | Rezurock | 200.0 mg/1 | Chemotherapy | Rho Kinase Inhibitor | ROCK 1, ROCK2 | Oral | July 16, 2021 | In Use | |
00378-0005-85 | 00378-0005 | Everolimus | Everolimus | 2.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct. 1, 2021 | In Use | |
00378-0006-85 | 00378-0006 | Everolimus | Everolimus | 3.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct. 1, 2021 | In Use | |
00378-0007-85 | 00378-0007 | Everolimus | Everolimus | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct. 1, 2021 | In Use |
Found 10,000 results in 6 milliseconds — Export these results